A prospective observational to determine incidence, nature, severity, and predictors of adverse events following vaccination with COVID-19 vaccines in Jordan
Latest Information Update: 26 Aug 2022
At a glance
- Drugs AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 26 Aug 2022 New trial record
- 23 Aug 2022 Results published in the Clinical Drug Investigation